AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21030194 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet self-management problem solving program
Number of subjects: 41
Study 19371823 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy within the first 30 days after index PCI
Number of subjects: 21009
Study 19371823 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy between 30 days and 6 months after index PCI
Number of subjects: 21009
Study 19371823 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy beyond 6 months after index PCI
Number of subjects: 21009
Study 19371823 — intervention group
Group type: EXPERIMENTAL
Intervention: Undersizing of the coronary stent
Number of subjects: 21009
Study 19371823 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of malignancy
Number of subjects: 21009
Study 19371823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate coronary artery disease proximal to the culprit lesion
Number of subjects: 21009
Study 19371823 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis In Myocardial Infarction flow grade <3
Number of subjects: 21009
Study 19371823 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissection
Number of subjects: 21009
Study 19371823 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of aspirin
Number of subjects: 21009
Study 19371823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifurcation lesions
Number of subjects: 21009
Study 19371823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction <30%
Number of subjects: 21009
Study 19371823 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 21009
Study 16684262 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI/AM500
Number of subjects: 228
Study 16684262 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI/AM750
Number of subjects: 228
Study 16684262 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI (lansoprazole)/AM500
Number of subjects: 228
Study 16684262 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI (omeprazole)/AM500
Number of subjects: 228
Study 16684262 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI (rabeprazole)/AM500
Number of subjects: 228
Study 16684262 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI (lansoprazole)/AM750
Number of subjects: 228
Study 16684262 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI (omeprazole)/AM750
Number of subjects: 228
Study 16684262 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI (rabeprazole)/AM750
Number of subjects: 228
Study 15275944 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-event processing (negative)
Number of subjects: 0
Study 15275944 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-event processing (other types)
Number of subjects: 0
Study 15275944 — intervention group
Group type: COMPARATOR
Intervention: Control group (no post-event processing specified)
Number of subjects: 0
Study 11521725 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab (single-agent)
Number of subjects: 206
Study 11521725 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab plus paclitaxel (weekly)
Number of subjects: 206
Study 11521725 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab plus docetaxel
Number of subjects: 206
Study 11521725 — intervention group
Group type: COMPARATOR
Intervention: docetaxel ± trastuzumab
Number of subjects: 206
Study 11521725 — intervention group
Group type: COMPARATOR
Intervention: aromatase inhibitor ± trastuzumab
Number of subjects: 206
Study 11521725 — intervention group
Group type: COMPARATOR
Intervention: CMF ± trastuzumab
Number of subjects: 206
Study 11521725 — intervention group
Group type: EXPERIMENTAL
Intervention: vinorelbine + trastuzumab
Number of subjects: 206
Study 11521725 — intervention group
Group type: EXPERIMENTAL
Intervention: epirubicin-cyclophosphamide (EC) + trastuzumab
Number of subjects: 206
Study 11521725 — intervention group
Group type: COMPARATOR
Intervention: epirubicin-cyclophosphamide (EC) alone
Number of subjects: 206
Study 9220306 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg losartan
Number of subjects: 129
Study 9220306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 7966805 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg elevation (foot elevated 30 cm above heart level)
Number of subjects: 30
Study 7966805 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leg elevation)
Number of subjects: 30
Study 2957859 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 67
Study 2957859 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefo‐Dolpasse
Number of subjects: 67
Study 2957859 — intervention group
Group type: COMPARATOR
Intervention: Other infusion solutions
Number of subjects: 67
Study 29637407 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal Doppler monitoring (EDM) for goal-directed fluid therapy
Number of subjects: 50
Study 29637407 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid management (Control)
Number of subjects: 50
Study 29637407 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal Doppler monitoring (EDM)
Number of subjects: 50
Study 30634208 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC) 0.5 g/pill, 3 pills each time, 3 times per day for 90 days
Number of subjects: 100
Study 30634208 — intervention group
Group type: COMPARATOR
Intervention: Control group (Leflunomide (LEF) Tablet 0.1 g/tablet, 1 tablet each time, once every evening for 90 days)
Number of subjects: 100
Study 25330327 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein-low carbohydrate (HPLC) diet (30/35/35% of energy from protein/carbohydrate/fat)
Number of subjects: 16
Study 25330327 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate-low protein (HCLP) diet (5/60/35% of energy from protein/carbohydrate/fat)
Number of subjects: 16
Study 22508307 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% UC781 gel
Number of subjects: 25
Study 22508307 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% UC781 gel
Number of subjects: 25
Study 22508307 — intervention group
Group type: EXPERIMENTAL
Intervention: UC781 gel (both concentrations)
Number of subjects: 25
Study 22508307 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 25
Study 20502386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine/midazolam (K/M)
Number of subjects: 23
Study 20502386 — intervention group
Group type: COMPARATOR
Intervention: Etomidate/fentanyl (E/F)
Number of subjects: 23
Study 17904561 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified technique (Joel-Cohen-Stark)
Number of subjects: 600
Study 17904561 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (Pfannenstiel-Kerr)
Number of subjects: 600
Study 16253582 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild bleeding
Number of subjects: 26452
Study 16253582 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate bleeding
Number of subjects: 26452
Study 16253582 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe bleeding
Number of subjects: 26452
Study 12447162 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol initiated before hospital discharge
Number of subjects: 375
Study 12447162 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Heart Failure Society of America guidelines)
Number of subjects: 375
Study 10363611 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (2 x 250 mg)
Number of subjects: 40
Study 10363611 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (6 Mio. KIU)
Number of subjects: 40
Study 10363611 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits ('Bioline' by Jostra)
Number of subjects: 40
Study 10363611 — intervention group
Group type: COMPARATOR
Intervention: No special measures (control group)
Number of subjects: 40
Study 7669486 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride 50 mg
Number of subjects: 8
Study 7669486 — intervention group
Group type: COMPARATOR
Intervention: Thyrotropin release hormone (TRH)
Number of subjects: 8
Study 2104091 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg nicardipine
Number of subjects: 0
Study 2104091 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nicardipine
Number of subjects: 0
Study 2104091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 340945 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline 5 mg
Number of subjects: 17
Study 340945 — intervention group
Group type: EXPERIMENTAL
Intervention: aminophylline 400 mg
Number of subjects: 17
Study 340945 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline 5 mg plus aminophylline 400 mg
Number of subjects: 17
Study 340945 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline 2.5 mg
Number of subjects: 17
Study 340945 — intervention group
Group type: EXPERIMENTAL
Intervention: aminophylline 200 mg
Number of subjects: 17
Study 340945 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline 2.5 mg plus aminophylline 200 mg
Number of subjects: 17
Study 340945 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 30986115 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric squat exercise against low load
Number of subjects: 26
Study 30986115 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric squat exercise against medium load
Number of subjects: 26
Study 30986115 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric squat exercise against high load
Number of subjects: 26
Study 30986115 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery period of 10 seconds after exercise
Number of subjects: 26
Study 30986115 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between men and women during high load condition
Number of subjects: 26
Study 28110911 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg semaglutide
Number of subjects: 388
Study 28110911 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg semaglutide
Number of subjects: 388
Study 28110911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study 25968008 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD) for 1 year
Number of subjects: 0
Study 25968008 — intervention group
Group type: COMPARATOR
Intervention: Gluten-containing diet (control)
Number of subjects: 0
Study 23565239 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion suppression (self-control task)
Number of subjects: 0
Study 21886067 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg bid, Amoxicillin 1 g bid, Clarithromycin 500 mg bid (LAC) for 14 days
Number of subjects: 91
Study 21886067 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bid, Levofloxacin 500 mg bid, Amoxicillin 1 g bid (OLA) for 7 days
Number of subjects: 91
Study 19697537 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol I (terminal cleaning, inspection and admission of new patient(s))
Number of subjects: 31
Study 19697537 — intervention group
Group type: COMPARATOR
Intervention: Protocol II (terminal cleaning, environmental cultures and closing of the room pending negative results)
Number of subjects: 31
Study 19697537 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol II (environmental cultures)
Number of subjects: 31
Study 16996194 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveform (Welch Allyn‐MRL PIC defibrillator; 70, 100, 150, 200, and 300 J)
Number of subjects: 139
Study 16996194 — intervention group
Group type: COMPARATOR
Intervention: Monophasic waveform (HP Codemaster XL; 100, 200, 300, 360, and 360 J)
Number of subjects: 139
Study 12749965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adenosine (50 microg/kg/min over 60min)
Number of subjects: 23
Study 12749965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adenosine
Number of subjects: 23
Study 12567694 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-artemether
Number of subjects: 150
Study 12567694 — intervention group
Group type: COMPARATOR
Intervention: Benflumetol tablet
Number of subjects: 150
Study 12567694 — intervention group
Group type: COMPARATOR
Intervention: Benflumetol capsule
Number of subjects: 150
Study 9347391 — intervention group
Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 169
Study 9347391 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 169
Study 8467249 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol (25,000 IU/day) for 48 to 65 months
Number of subjects: 93
Study 8467249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 3797879 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 40 mg/kg/day three times daily
Number of subjects: 367
Study 3797879 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 40 mg/kg/day two times daily
Number of subjects: 367
Study 30377755 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior mesenteric vein (IMV) approach with systematic medial mobilization (MM)
Number of subjects: 98
Study 30377755 — intervention group
Group type: COMPARATOR
Intervention: Inferior mesenteric artery (IMA) approach
Number of subjects: 98
Study 30377755 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches (IMV and IMA)
Number of subjects: 98
Study 29778129 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy (smelled two times daily for 20 min during 12 weeks)
Number of subjects: 100
Study 29778129 — intervention group
Group type: COMPARATOR
Intervention: Control (diluted milk)
Number of subjects: 100
Study 27114593 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (8 cycles)
Number of subjects: 549
Study 27114593 — intervention group
Group type: COMPARATOR
Intervention: BEACOPP (4 cycles escalated + 4 cycles baseline)
Number of subjects: 549
Study 25524333 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel pre-treatment (30-mg loading dose)
Number of subjects: 4033
Study 25524333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no pre-treatment)
Number of subjects: 4033
Study 23157722 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin girls compared to normal-weight girls
Number of subjects: 5226
Study 23157722 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight girls compared to normal-weight girls
Number of subjects: 5226
Study 23157722 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese girls compared to normal-weight girls
Number of subjects: 5226
Study 23157722 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin boys compared to normal-weight boys
Number of subjects: 5226
Study 23157722 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight boys compared to normal-weight boys
Number of subjects: 5226
Study 23157722 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese boys compared to normal-weight boys
Number of subjects: 5226
Study 20215968 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 5752
Study 20215968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5752
Study 17118830 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Blockade (SGB) in Group 1
Number of subjects: 50
Study 17118830 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 50
Study 15300117 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dk silicone hydrogel lenses
Number of subjects: 92
Study 15300117 — intervention group
Group type: COMPARATOR
Intervention: Low-Dk hydrogel lenses
Number of subjects: 92
Study 11207518 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day RACM regimen (rabeprazole 20 mg b.d., amoxicillin 750 mg b.d., clarithromycin 200 mg b.d., metronidazole 250 mg b.d.)
Number of subjects: 160
Study 11207518 — intervention group
Group type: COMPARATOR
Intervention: 7-day RAC regimen (rabeprazole 20 mg b.d., amoxicillin 750 mg b.d., clarithromycin 200 mg b.d.)
Number of subjects: 160
Study 9297192 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet aggregation measured with ADP 5 microM; collagen 2 micrograms/ml; arachidonic acid 0.75 microM; serotonin 1 microM; ristocetin 1.5 micrograms/ml
Number of subjects: 16
Study 9297192 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 16
Study 9297192 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma serotonin concentration in uremic patients
Number of subjects: 16
Study 8341175 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbimazole 30 mg once daily (group 1)
Number of subjects: 70
Study 8341175 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbimazole 15 mg twice daily (group 2)
Number of subjects: 70
Study 8341175 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbimazole 10 mg thrice daily (group 3)
Number of subjects: 70
Study 3550043 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled extracapsular surgery with careful cleaning of the cortical material and in-the-bag implantation of a posterior chamber intraocular lens
Number of subjects: 0
Study 3550043 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior chamber angle‐fixated lenses with flexible loops
Number of subjects: 0
Study 3550043 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior chamber lenses placed in the ciliary sulcus and in the bag
Number of subjects: 0
Study 29621945 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy intervention
Number of subjects: 0
Study 29455676 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmoscopy simulator training
Number of subjects: 17
Study 29455676 — intervention group
Group type: COMPARATOR
Intervention: Control group (no simulator training)
Number of subjects: 17
Study 27116983 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic rhFSH (n=352)
Number of subjects: 531
Study 27116983 — intervention group
Group type: COMPARATOR
Intervention: Imported rhFSH (n=179)
Number of subjects: 531
Study 24477825 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 40
Study 24477825 — intervention group
Group type: EXPERIMENTAL
Intervention: Video‐assisted laryngoscope
Number of subjects: 40
Study 22548962 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + aerobic exercise
Number of subjects: 304
Study 22548962 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + resistance exercise
Number of subjects: 304
Study 22548962 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + combined aerobic and resistance exercise
Number of subjects: 304
Study 22548962 — intervention group
Group type: COMPARATOR
Intervention: Diet only waiting-list control
Number of subjects: 304
Study 20509780 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention Group (EIG)
Number of subjects: 869
Study 20509780 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group (UCG)
Number of subjects: 869
Study 18692244 — intervention group
Group type: EXPERIMENTAL
Intervention: argon laser trabeculoplasty plus betaxolol
Number of subjects: 255
Study 18692244 — intervention group
Group type: COMPARATOR
Intervention: no initial treatment
Number of subjects: 255
Study 17363538 — intervention group
Group type: EXPERIMENTAL
Intervention: Indisulam (700 mg/m2 as a single i.v. dose on day one)
Number of subjects: 44
Study 17363538 — intervention group
Group type: EXPERIMENTAL
Intervention: Indisulam (130 mg/m2 given on days 1 to 5 as a daily infusion)
Number of subjects: 44
Study 17363538 — intervention group
Group type: EXPERIMENTAL
Intervention: Indisulam (both treatment schedules)
Number of subjects: 44
Study 12578340 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive aortic valve replacement (partial upper sternotomy)
Number of subjects: 40
Study 12578340 — intervention group
Group type: COMPARATOR
Intervention: Conventional aortic valve replacement (complete median sternotomy)
Number of subjects: 40
Study 11132373 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg elemental iron twice-weekly for 12 months
Number of subjects: 412
Study 11132373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 9080738 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cetylpyridinium chloride mouthwash
Number of subjects: 129
Study 9080738 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 129
Study 8336992 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms)
Number of subjects: 2
Study 8336992 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (500 micrograms/day and 1500 micrograms/day)
Number of subjects: 2
Study 8336992 — intervention group
Group type: COMPARATOR
Intervention: Octreotide (50 micrograms s.c.)
Number of subjects: 2
Study 8336992 — intervention group
Group type: COMPARATOR
Intervention: Octreotide (double-blind check)
Number of subjects: 2
Study 3087677 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil
Number of subjects: 9
Study 3087677 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 9
Study 29327104 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy added to usual pharmacotherapy
Number of subjects: 0
Study 29327104 — intervention group
Group type: COMPARATOR
Intervention: Usual pharmacotherapy alone
Number of subjects: 0
Study 27871559 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anesthesia (remifentanil + sevoflurane)
Number of subjects: 130
Study 27871559 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia (remifentanil + propofol)
Number of subjects: 130
Study 27871559 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anesthesia
Number of subjects: 130
Study 27871559 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia
Number of subjects: 130
Study 23877585 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR)
Number of subjects: 923
Study 23877585 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper Questionnaire (PQ)
Number of subjects: 923
Study 23877585 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Digital Assistant (PDA)
Number of subjects: 923
Study 23877585 — intervention group
Group type: COMPARATOR
Intervention: Personal Computer (PC)
Number of subjects: 923
Study 23548697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine
Number of subjects: 70
Study 23548697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 20865580 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg intravenous dexketoprofen
Number of subjects: 50